Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

Define "positive results". RXI's definition is BS.

Example: While the 11/29/2017 skin lightener PR states, "We are very pleased with these positive results", it doesn't actually say just what those results are. No photos, as usual (a rather large red flag, that one). And, most importantly, no deal from any cosmetic company.

Research for the skin lightener is being out-licensed (ie, effective abandoned) in favor of only the immuno-oncology (IO) pipeline. IO is in the pre-clinical phase and RXI has no money (but don't fear, massive LPC dilution is occurring as I write this missive).

To me, RXI's track record is one of failure. It has not "validated" the vaunted platform by delivering a marketable product. In fact, the only product that's making good progress, Samcyprone, isn't an RNAi product and was only purchased to develop and bring in revenue. Samcyprone is also being out-licensed.